October 15, 2019

Rituxan Biosimilar IBI301 Shows Similar Safety, Efficacy to Original in B-cell Lymphomas, Trials Show

News

IBI301, a biosimilar to Rituxan (rituximab), has a similar response rate to the original compound in people with B-cell lymphomas, and behaves similarly inside the body, preliminary results of two trials ... Read more

May 23, 2019

IBI301 (Biosimilar of Rituxan) Meets Primary Endpoints in 2 Clinical Trials in China for B-cell Lymphomas

News

IBI301, a biosimilar of Rituxan (rituximab), behaves similarly in the body and has a similar efficacy as the original product in patients with B-cell cancers, according to results from two ... Read more